 HOUSTON, July 13, 2021 PRNewswire -- Moleculin Biotech, Inc. , Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has received approval from the Bioethics Committee of the Medical University of Karol Marcinkiewicz in Poznań Ethics Committee as well as an allowance from the Polish Department of Registration of Medicinal Products URPL for a protocol amendment for its Phase 12 evaluating Annamycin for the treatment of subjects with acute myeloid leukemia AML that is refractory to or relapsed after induction therapy. Annamycin is the Companys next-generation anthracycline that has demonstrated a lack of cardiotoxicity in recently conducted human clinical trials for the treatment of AML. 